<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-11-02-2026-shutterstock_1116008312-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-11-02-2026-shutterstock_1116008312-430x241.jpg"/></p>
<p>此次合作将结合 Insilico Medicine 在小分子设计、候选分子筛选和靶点识别方面的技术。来源：tilialucida / Shutterstock.com。</p>
<p>Insilico Medicine 已与中国医疗系统（CMS）在中枢神经系统（CNS）和自身免疫疾病的多个项目上宣布了几项人工智能药物发现合作。</p>
<p>两家公司计划共同开发至少两个研发项目，利用 Insilico Medicine 的人工智能平台以及 CMS 在临床开发方面的专业知识。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Alaunos Therapeutics Inc 的基因修饰细胞疗法针对...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Bristol-Myers Squibb Co 的 BMS-90011</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>根据协议，Insilico Medicine 将为每个项目获得研发资金。</p>
<p>此次合作将结合 Insilico Medicine 的 Pharma.AI 平台和小分子设计、候选分子筛选及靶点识别技术，以及 CMS 在监管规划、临床试验和商业化方面的经验。</p>
<p>双方旨在覆盖从早期发现到将新疗法推向市场的整个价值链。</p>
<p>项目团队将共同优化决策，旨在缩短开发周期并提高临床成功率。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>CMS 董事长、首席执行官、总裁兼执行董事 LAM Kong 表示：“我们将继续丰富我们的产品线，拥有全球首创（FIC）和最佳（BIC）创新资产，高效推进其临床研究、开发和商业化，推动科学成就持续转化为临床实践。”</p>
<p>Insilico Medicine 和 CMS 打算整合各自的资源和专业知识，加速实验室发现转化为临床开发，最终为患者提供更多治疗方案。</p>
<p>Insilico Medicine 联合首席执行官兼首席科学官 Feng Ren 表示：“在这一合作框架下，我们期待利用资源共享和联合决策，显著缩短高潜力创新药物的开发周期，提高转化效率和临床成功率，加速更多创新分子从 ‘概念验证’ 到真正 ‘惠及患者’ 的旅程。</p>
<p>“展望未来，双方将继续在产品线布局、临床策略和全球合作方面深化多维度合作，进一步提高创新药物的可及性，为患者提供更多差异化的治疗选择。”</p>
<p>上个月，Insilico 与 Servier 达成了一项价值高达 8.88 亿美元的多年研发合作，以开发和发现新的肿瘤治疗方案。</p>

康哲药业

<p>Insilico Medicine 与中国医疗系统（CMS）达成合作，启动针对中枢神经系统（CNS）和自身免疫疾病的人工智能药物发现合作。此次合作将利用 Insilico 的 Pharma.AI 平台进行小分子设计和候选药物筛选，并结合 CMS 在临床开发方面的专业知识。Insilico 将为每个项目获得研发资金，旨在简化药物开发流程并提高临床成功率。两家公司计划在临床战略和全球合作伙伴关系方面加深合作，以改善患者获得创新治疗的机会</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-11-02-2026-shutterstock_1116008312-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-11-02-2026-shutterstock_1116008312-430x241.jpg"/></p>
<p>The collaboration will combine Insilico Medicine’s technologies for small-molecule design, candidate molecules screening, and target identification. Credit: tilialucida / Shutterstock.com.</p>
<div class="lb-trans"><p>此次合作将结合 Insilico Medicine 在小分子设计、候选分子筛选和靶点识别方面的技术。来源：tilialucida / Shutterstock.com。</p>
</div><p>Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous system (CNS) and autoimmune diseases.</p>
<div class="lb-trans"><p>Insilico Medicine 已与中国医疗系统（CMS）在中枢神经系统（CNS）和自身免疫疾病的多个项目上宣布了几项人工智能药物发现合作。</p>
</div><p>The companies plan to jointly develop at least two research and development (R&amp;D) programmes using Insilico Medicine’s AI platform alongside CMS’ expertise in clinical development.</p>
<div class="lb-trans"><p>两家公司计划共同开发至少两个研发项目，利用 Insilico Medicine 的人工智能平台以及 CMS 在临床开发方面的专业知识。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Alaunos Therapeutics Inc's Gene-Modified Cell Therapy to Targ...</h4>
<div class="lb-trans"><h4>NPVM: Alaunos Therapeutics Inc 的基因修饰细胞疗法针对...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Bristol-Myers Squibb Co's BMS-90011</h4>
<div class="lb-trans"><h4>NPVM: Bristol-Myers Squibb Co 的 BMS-90011</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Under the agreement, Insilico Medicine will receive R&amp;D funding for each programme.</p>
<div class="lb-trans"><p>根据协议，Insilico Medicine 将为每个项目获得研发资金。</p>
</div><p>The collaboration will combine Insilico Medicine’s Pharma.AI platform and technologies for small-molecule design, candidate molecules screening, and target identification with CMS’s experience in regulatory planning, clinical trials, and commercialisation.</p>
<div class="lb-trans"><p>此次合作将结合 Insilico Medicine 的 Pharma.AI 平台和小分子设计、候选分子筛选及靶点识别技术，以及 CMS 在监管规划、临床试验和商业化方面的经验。</p>
</div><p>Both entities aim to cover the entire value chain from early discovery to bringing new therapies to market.</p>
<div class="lb-trans"><p>双方旨在覆盖从早期发现到将新疗法推向市场的整个价值链。</p>
</div><p>Project teams will jointly optimise decision-making, aiming to shorten development timelines and improve clinical success rates.</p>
<div class="lb-trans"><p>项目团队将共同优化决策，旨在缩短开发周期并提高临床成功率。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>CMS chairman, CEO, president and executive director LAM Kong said: “We continue to enrich our pipeline with global first-in-class (FIC) and best-in-class (BIC) innovative assets, efficiently advancing their clinical research, development, and commercialisation to empower the continuous translation of scientific achievements into clinical practice.”</p>
<div class="lb-trans"><p>CMS 董事长、首席执行官、总裁兼执行董事 LAM Kong 表示：“我们将继续丰富我们的产品线，拥有全球首创（FIC）和最佳（BIC）创新资产，高效推进其临床研究、开发和商业化，推动科学成就持续转化为临床实践。”</p>
</div><p>Insilico Medicine and CMS intend to integrate their resources and expertise to accelerate laboratory discoveries into clinical development, ultimately providing more treatments for patients.</p>
<div class="lb-trans"><p>Insilico Medicine 和 CMS 打算整合各自的资源和专业知识，加速实验室发现转化为临床开发，最终为患者提供更多治疗方案。</p>
</div><p>Insilico Medicine co-CEO and chief scientific officer Feng Ren said: “Under this collaboration framework, we look forward to leveraging resource sharing and joint decision making to significantly shorten the development cycle of high-potential innovative drugs, enhance translational efficiency and clinical success rates, and accelerate the journey of more innovative molecules from ‘proof of concept’ to truly ‘benefiting patients’.</p>
<div class="lb-trans"><p>Insilico Medicine 联合首席执行官兼首席科学官 Feng Ren 表示：“在这一合作框架下，我们期待利用资源共享和联合决策，显著缩短高潜力创新药物的开发周期，提高转化效率和临床成功率，加速更多创新分子从 ‘概念验证’ 到真正 ‘惠及患者’ 的旅程。</p>
</div><p>“Going forward, the two parties will continue to deepen multi-dimensional collaboration in pipeline layout, clinical strategy, and global partnerships, further improving the accessibility of innovative medicines, providing patients with more differentiated treatment options.”</p>
<div class="lb-trans"><p>“展望未来，双方将继续在产品线布局、临床策略和全球合作方面深化多维度合作，进一步提高创新药物的可及性，为患者提供更多差异化的治疗选择。”</p>
</div><p>Last month, Insilico entered a multi-year R&amp;D collaboration with Servier, worth up to $888m, to develop and discover new oncology therapies.</p>
<div class="lb-trans"><p>上个月，Insilico 与 Servier 达成了一项价值高达 8.88 亿美元的多年研发合作，以开发和发现新的肿瘤治疗方案。</p>
</div>

Insilico 与康哲药业启动针对中枢神经系统疾病的药物研发合作